Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mankind PharmaBOM:543904 -2.10%90 Interest Coverage is 4.99 as of Mar. 2026, which is 88% below its 10-year median of 40.76. GuruFocus rates BOM:543904 with a GF Score™ of 90/100 and a GF Value™ of ₹2,934.91 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 687 Drug Manufacturers companies, Mankind Pharma ranks worse than 74.24% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Mankind Pharma's
Operating Income
for the
three
months ended in Mar. 2026 was ₹7,068 Mil. Mankind Pharma's Interest Expense for the
three
months ended in Mar. 2026 was ₹-1,418 Mil.
Mankind Pharma's interest coverage for the quarter that ended in Mar. 2026 was 4.99.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Mankind Pharma's Interest Coverage or its related term are showing as below:
BOM:543904'
s Interest Coverage Range Over the Past 10 Years
Min: 4.27 Med: 40.76 Max: 83.38
Current: 4.27
BOM:543904's Interest Coverage is ranked worse than 74.24% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs BOM:543904: 4.27
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Mankind Pharma Interest Coverage Related Terms
Mankind Pharma Interest Coverage Historical Data
* Premium members only.
The historical data trend for Mankind Pharma's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:543904 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mankind Pharma (BOM:543904) has a Interest Coverage of 4.99 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Mankind Pharma and its competitors. This is 88% below median its historical median of 40.76. Over the past decade, Mankind Pharma's Interest Coverage has ranged from 4.27 to 83.38. According to the industry distribution chart, Mankind Pharma ranks #510 out of 687 companies in the Drug Manufacturers industry, placing it in the top 74.2%.
Is Mankind Pharma's Interest Coverage too high?
Mankind Pharma's current Interest Coverage of 4.99 is 88% below median its 10-year median of 40.76. Over the past 10 years, this metric has ranged from a low of 4.27 to a high of 83.38. The Drug Manufacturers industry median Interest Coverage is 12.75. Mankind Pharma's value of 4.99 is 60.9% below this industry median. Based on the distribution chart, Mankind Pharma ranks #510 out of 687 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Mankind Pharma has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mankind Pharma ranks #510 out of 687 companies for Interest Coverage. This places Mankind Pharma in the lower half of its industry. The industry median Interest Coverage is 12.75. Mankind Pharma's value of 4.99 is 60.9% below this benchmark. Historically, Mankind Pharma's own Interest Coverage has ranged from 4.27 to 83.38 over the past decade. While the company's 10-year median is 40.76 vs. the industry median of 12.75, Mankind Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mankind Pharma's current Interest Coverage of 4.99 is 60.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Mankind Pharma and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mankind Pharma's current Interest Coverage is 4.99, which is 88% below median its own 10-year median of 40.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,934.91, compared to a current price of ₹2,491.45 — trading 15.1% below its estimated fair value. The current Interest Coverage is 4.99, which is 88% below median its 10-year median of 40.76 and 60.9% below the Drug Manufacturers industry median of 12.75. Mankind Pharma's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current Interest Coverage is 4.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mankind Pharma (BOM:543904) Overvalued in 2026?
Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued.
The current stock price of ₹2,491.45 is trading 15.1% below its estimated GF Value™ of ₹2,934.91.
GuruFocus considers Mankind Pharma to be Modestly Undervalued.
Key valuation signals for BOM:543904:
Interest Coverage: 4.99 (88% below median its 10-year median of 40.76)
GF Value™: ₹2,934.91 vs. price of ₹2,491.45 (15.1% below fair value)
Industry Position: 60.9% below the Drug Manufacturers median (#510 of 687)
No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
90GF Score
Get the complete analysis for BOM:543904
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543904 has been successfully added to your 
